SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 29.95-3.7%9:52 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert K. who wrote (8288)1/14/1999 4:20:00 PM
From: aknahow  Read Replies (1) of 17367
 
Have just heard that the Meningococcemia trial has accrued 333 patients. The last 12 came from the U.K.

I don't know when the trial will end, but would think it will be soon, meaning a few more weeks. Few for me means 4 to 6. This is only my opinion, so it is worth even less than yours.<g>

I remain more optimistic about XOMA than ever. I do not see a problem with the fact that accruals have continued past Dec. Do hope that XOMA clarifies this and I do wish the U.K. data on the PHLS site would update faster.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News